FDA lists recall of Apothecary Pharma tirzepatide vials over sterility concerns

The nationwide recall covers 22 vials of a specific tirzepatide product and one vial of a separate NAD+ product. The FDA lists it as ongoing.
Loading coverage...
Independent reporting from across Vermont.

The nationwide recall covers 22 vials of a specific tirzepatide product and one vial of a separate NAD+ product. The FDA lists it as ongoing.

The nonprofit operator signed a letter of intent for a property. An Oct. 7 report described zoning and council decisions still ahead.

The Sept. 15 workforce announcement followed an operational review begun in April. The system also identified changes to remote-care programs.

The system, which operates in Vermont and northern New York, announced a net reduction of 144 full-time-equivalent positions after adding 55 roles. The figures are not a count of people laid off.

The Burlington-led project would test treatments on virtual patient models. Federal funding is tied to research milestones over as many as five years.

Researchers will develop artificial intelligence models for testing possible treatments before they are used on critically ill patients.
Verified schedules will appear here. Check the organizer's official schedule for the latest information.